Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Pharmacological treatments for non-alcoholic steatohepatitis (NASH) are still unsatisfactory. Fibrosis is the most significant predictor of mortality and many anti-fibrotic agents are under evaluation. Herein, we assessed in vitro the effects of the FXR agonist obeticholic acid (OCA) and the dual FXR/TGR5 agonist INT-767 in a well-established co-culture NASH model. Co-cultures of human hepatoma and hepatic stellate (HSCs) cells were exposed to free fatty acids (FFAs) alone or in combination with OCA or INT-767. mRNA expression of HSCs activation markers and FXR engagement were evaluated at 24, 96 and 144 hours. Collagen deposition and metalloproteinase 2 and 9 (MMP2-9) activity were compared to tropifexor and selonsertib. FFAs induced collagen deposition and MMP2-9 activity reduction. Co-treatment with OCA or INT-767 did not affect ACTA2 and COL1A1 expression, but significantly reduced FXR and induced SHP expression, as expected. OCA induced a dose-dependent reduction of collagen and induced MMP2-9 activity. Similarly, INT-767 induced collagen reduction at 96 h and a slight increase in MMP2-9. Tropifexor and Selonsertib were also effective in collagen reduction but showed no modulation of MMP2-9. All tested compounds reduced collagen deposition. OCA exerted a more potent and long-lasting effect, mainly related to modulation of collagen turn-over and MMP2-9 activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, OCA and the improved FXR/TGR5 agonist INT-7667, induced an in-vitro dosedependent reduction of collagen and increased MMP2-9 activity, [86]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Bataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931
Self-citationTranscriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Calkin, A. C., & Tontonoz, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3312 · Cited by 779
Research works printed but not linked: 1
- https://www.gilead.com/news-and-press/press-room/press-releases/2019/2/gilead-announces-topline-data-from-phase-3-stellar4-study-of-selonsertib-in-compensated-cirrhosis-f4-due-to-nonalcoholic-steatohepatitis-nash (2019).
Cited by
In Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
“Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis.”
BackgroundInfluentialRegulation of bile acids and their receptor FXR in metabolic diseases
Li, Y., Wang, L., Qing, Y., Luo, L., & Xiong, Y. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1447878 · Cited by 126
Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
Fang, T., Wang, H., Pan, X., Little, P. J., Xu, S., & Weng, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.65044 · Cited by 114
“In a NASH model, OCA had higher efficacy and longer half-life than the dual FXR/TGR5 agonist INT-767 [139].”
BackgroundNew Drugs for Hepatic Fibrosis
Shan, L., Wang, F., Zhai, D., Meng, X., Liu, J., & Lv, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.874408 · Cited by 83
Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
Mori, H., Svegliati‐Baroni, G., Marzioni, M., Nicola, F. D., Santori, P., Maroni, L., Abenavoli, L., & Scarpellini, E. (2022) · Metabolites · doi:10.3390/metabo12070647 · Cited by 85
Metadata
- Authors
- Anfuso, B., Tiribelli, C., Adorini, L., & Rosso, N.
- Affiliations
- AREA Science Park (IT)
- Intercept Pharmaceuticals (United States) (US)
- Corresponding author
- Rosso, Natalia
- Venue
- Scientific Reports
- Published
- 2020-02-03
- Volume
- 10
- Issue
- 1
- Pages
- 1699-1699
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC6997404
- OpenAlex
- W3004413824
- Cited by
- 43
- References
- 41
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 8 · 2021: 5 · 2020: 4
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Intercept Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- obeticholic acid, nonalcoholic steatohepatitis, liver fibrosis, collagen deposition, hepatic stellate cells, FXR agonists, TGR5 agonists, free fatty acids, matrix metalloproteinases, selonsertib, antifibrotic therapy
- MeSH terms
- Benzamides, Bile Acids and Salts, Cell Line, Chenodeoxycholic Acid, Collagen, Fatty Acids, Nonesterified, Humans, Imidazoles, Isoxazoles, Liver, Pyridines, RNA-Binding Proteins, Receptors, Cytoplasmic and Nuclear, Coculture Techniques, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, Hepatocytes, Protein Kinase Inhibitors, Benzothiazoles, Hepatic Stellate Cells, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. https://app.cochat.ai/papers/10.1038/s41598-020-58562-x
- The paper
- Anfuso, B., Tiribelli, C., Adorini, L., & Rosso, N. (2020). Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. Scientific Reports. https://doi.org/10.1038/s41598-020-58562-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.